ArticleeLife2016
Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 90 citations in OpenAlex.
- Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma.Nature communications · 2026Article
- Relapsed rhabdoid tumours and other non-nephroblastoma childhood and adolescent kidney tumours: perspectives from the HARMONICA collaboration.Nature reviews. Urology · 2026Review
- TFEB coordinates autophagosome biogenesis and ribophagy during starvation via SQSTM1.Science advances · 2026Article
- SFPQ-TFE3 reciprocally regulates mTORC1 and induces lineage plasticity in a mouse model of renal tumorigenesis.Nature communications · 2025Article
- RNA-mediated condensation of TFE3 oncofusions facilitates transcriptional hub formation to promote translocation renal cell carcinoma.Nature communications · 2025Article
- Autophagy in cancer and protein conformational disorders.FEBS letters · 2025Review
- Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma.bioRxiv : the preprint server for biology · 2025Article
- Targeting Lysosomal Dysfunction and Oxidative Stress in Age-Related Macular Degeneration.Antioxidants (Basel, Switzerland) · 2025Review
- An engineered tumor organoid model reveals cellular identity and signaling trajectories underlying SFPQ-TFE3 driven translocation RCC.iScience · 2025Article
- Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma.Nature metabolism · 2025Article
- GADD45α is a direct target of TFEB and contributes to tacrolimus-induced chronic nephrotoxicity.JCI insight · 2025Article
- Age-related TFEB downregulation in proximal tubules causes systemic metabolic disorders and occasional apolipoprotein A4-related amyloidosis.JCI insight · 2024Article
- The Spectrum of Renal "TFEopathies": Flipping the mTOR Switch in Renal Tumorigenesis.Physiology (Bethesda, Md.) · 2024Review
- TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma.bioRxiv : the preprint server for biology · 2024Article
- From the regulatory mechanism of TFEB to its therapeutic implications.Cell death discovery · 2024Review
- The post-translational regulation of transcription factor EB (TFEB) in health and disease.EMBO reports · 2023Review
- Balancing lysosome abundance in health and disease.Nature cell biology · 2023Review
- A new glance at autophagolysosomal-dependent or -independent function of transcriptional factor EB in human cancer.Acta pharmacologica Sinica · 2023Review
- Functional TFEB activation characterizes multiple models of renal cystic disease and loss of polycystin-1.American journal of physiology. Renal physiology · 2023Article
- TFEB-mediated lysosomal exocytosis alleviates high-fat diet-induced lipotoxicity in the kidney.JCI insight · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 4 countries.
Alessia CalcagnìTelethon Institute of Genetics and Medicine, TIGEM, Pozzuoli, Naples, Italy.
Lotte KorsTelethon Institute of Genetics and Medicine, TIGEM, Pozzuoli, Naples, Italy.
Eric VerschurenDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Rossella De CegliTelethon Institute of Genetics and Medicine, TIGEM, Pozzuoli, Naples, Italy.
Nicolina ZampelliTelethon Institute of Genetics and Medicine, TIGEM, Pozzuoli, Naples, Italy.
Edoardo NuscoTelethon Institute of Genetics and Medicine, TIGEM, Pozzuoli, Naples, Italy.
Stefano ConfalonieriMolecular Medicine Program, European Institute of Oncology, Milan, Italy.
Giovanni BertalotMolecular Medicine Program, European Institute of Oncology, Milan, Italy.
Salvatore PeceMolecular Medicine Program, European Institute of Oncology, Milan, Italy.
Carmine SettembreTelethon Institute of Genetics and Medicine, TIGEM, Pozzuoli, Naples, Italy.
Gabriel G MaloufDepartment of Medical Oncology Groupe Hospitalier Pitie-Salpetriere, University Paris 6, Paris, France.
Jaklien C LeemansDepartment of Pathology, Academical Medical Center, Amsterdam, The Netherlands.
Emile de HeerDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Marco SalvatoreIRCCS-SDN, Naples, Italy.
Dorien Jm PetersDepartment of Human Genetics, Leiden University Medical Center, Leiden, Netherlands.
Pier Paolo Di FioreMolecular Medicine Program, European Institute of Oncology, Milan, Italy.
Andrea BallabioTelethon Institute of Genetics and Medicine, TIGEM, Pozzuoli, Naples, Italy.ORCID http://orcid.org/0000-0003-1381-4604
Telethon Institute Of Genetics And Medicine · ITLeiden University Medical Center · NLAmsterdam UMC Location University of Amsterdam · NLBaylor College of Medicine · USUniversity of Milan · ITEuropean Institute of Oncology · ITIFOM · ITSDN Istituto di Ricerca Diagnostica e Nucleare · ITSorbonne Université · FR
Funding
MODULATION OF CELLULAR CLEARANCE TO TREAT HUMAN DISEASER01NS078072 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI BALLABIO, ANDREA · 2012 to 2020
$3.1MEuropean Research Council 250154NINDS NIH HHS R01 NS078072
Abstract
PubMed holds no abstract for this paper.
Indexed as
cancer biologyhuman biologymedicinemouserenal cell carcinomaTFEBWNT pathway
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.